Vor Biopharma INC Form 4 insider transactions

Ra Capital Management, L.P. and 3 others reported changes in beneficial ownership of Vor Biopharma Inc. common stock on July 16, 2026.

Vor Biopharma Inc. reports that Director David Zaccardelli was granted stock options for 42,658 shares.

RA Capital Management reports the acquisition of stock options by Dr. Andrew Levin on behalf of the investment fund.

Director Michel Detheux was granted 57,162 stock options in Vor Biopharma Inc. as part of standard equity compensation.

Director Fouad Namouni was granted 56,549 stock options in Vor Biopharma Inc. as part of a standard equity compensation arrangement.

Director Wouter Joustra was granted 57,162 stock options in Vor Biopharma Inc. as part of a standard equity compensation plan.

Director Erez Kalir was granted 57,162 stock options in Vor Biopharma Inc. as part of a standard equity compensation arrangement.

Director Alexander Cumbo was granted 56,345 stock options in Vor Biopharma Inc. as part of a standard equity compensation arrangement.

Director Daniella Beckman was granted 53,283 stock options in Vor Biopharma Inc. as part of a standard equity compensation plan.

Director Andrew David Levin was granted 57,162 stock options in Vor Biopharma Inc. as part of his service arrangement.

RA Capital Management, a major shareholder and director-affiliated entity, sold 165,150 shares of Vor Biopharma Inc. at a weighted average price of $15.77.

RA Capital Management, L.P. reported the sale of 630,374 shares of Vor Biopharma Inc. common stock across two transactions in April 2026.

RA Capital Management has disclosed the sale of approximately 737,989 shares of Vor Biopharma Inc. across three days in April 2026.

RA Capital Management, L.P. and its affiliates have reported the sale of a significant number of Vor Biopharma Inc. common shares across multiple transactions.

RA Capital Management, L.P. and its affiliates have reported significant transactions involving the sale of Vor Biopharma Inc. common stock.

RA Capital Management, a significant shareholder and director, increased its indirect beneficial ownership in Vor Biopharma Inc. by acquiring common stock and stock options.

Vor Biopharma Inc. Director Wouter Joustra acquired 3,000 stock options with an exercise price of $12.8, vesting monthly over three years.

Vor Biopharma director Andrew David Levin was granted 3,000 stock options with an exercise price of $12.80, vesting over 36 months.

Vor Biopharma's CFO, Sandesh Mahatme, reported the cancellation of restricted stock units and the grant of new stock options following a reverse stock split.

Vor Biopharma's Chief Development Officer, Qing Zuraw, had her stock options repriced to $8.18 per share following a reverse stock split and significant stock value decline.

Vor Biopharma Inc. CEO Jean-Paul Kress's stock options were repriced to $8.18 per share following a reverse stock split and board approval.

RA Capital Management and its affiliates reported multiple sales of Vor Biopharma common stock in late October 2025, significantly reducing their beneficial ownership.

RA Capital Management, a 10% owner and director of Vor Biopharma Inc., sold a total of 221,166 shares of common stock over three days in late October 2025.

RA Capital Management and its affiliated funds sold 117,050 shares of Vor Biopharma Inc. common stock in late October 2025 through pre-planned transactions.

Reprogrammed Interchange LLC, a 10% owner and director, sold over 37,000 shares of Vor Biopharma common stock in October 2025 under a Rule 10b5-1 plan.

Reprogrammed Interchange LLC and Reid Hoffman reported significant sales of Vor Biopharma Inc. common stock in mid-October 2025, reducing their beneficial ownership.

RA Capital Management and its affiliated funds, including directors Peter Kolchinsky and Rajeev Shah, sold 464,025 shares of Vor Biopharma Inc. common stock over three days in October 2025 under a Rule 10b5-1 plan.

Reprogrammed Interchange LLC, a 10% owner and entity associated with director Reid Hoffman, sold 96,657 shares of Vor Biopharma common stock for approximately $3 million.

Reprogrammed Interchange LLC, a 10% owner and director of Vor Biopharma Inc., sold 124,146 shares of common stock for approximately $4.1 million over two days.

Reprogrammed Interchange LLC, a 10% owner and director, sold 98,387 shares of Vor Biopharma Inc. common stock across multiple transactions in early October 2025.